Idiopathic Pulmonary Fibrosis and Serum Bank

Completed

• Conditions: Lung Diseases, Interstitial; Idiopathic Pulmonary Fibrosis
• Interventions: Biological: Blood sample collection

• Registration Number: NCT04016168
• Lead Sponsor: Rennes University Hospital

Brief Summary

Idiopathic pulmonary fibrosis (IPF) is the most common form of chronic idiopathic diffuse interstitial lung disease (DILD) in adults. It is a fibroproliferative, irreversible disease of unknown cause, usually progressive, occurring mainly from the age of 60 and limited to the lungs. IPF is a serious disease with a median survival rate at diagnosis of 3 years.

The aim of the study is to set up a biocollection of serum from patients in a context of idiopathic DILD and a possible or confirmed diagnosis of common interstitial lung disease by chest CT.

Patients will be recruited at the consultations of the Rennes Rare Lung Disease Competence Centre. These will be patients in stable condition or in acute exacerbation of IPF.

Detailed Description

This study will initially focus on circulating serum CD163 markers, but a broader proteomics approach could be considered in a second phase to look for other markers of lung diseases.

Study Timeline

• Study Start: 2014-10-22
• Study First Submitted: 2019-07-08
• Study First Submitted QC: 2019-07-10
• Study First Posted: 2019-07-11
• Primary Completion: 2022-12-28
• Study Completion: 2022-12-28
• Status Verified: 2023-11
• Last Update Submitted: 2023-11-27
• Last Update Posted: 2023-11-28

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 903

Inclusion Criteria

• Patients seen on an outpatient basis and in stable or acute condition
• Patient over 18 years of age.
• The inclusion criteria will be those edited by the American Thoracic Society (ATS) and the European Respiratory Society (ERS) to diagnosis IPF

Exclusion Criteria

• Patients who are unable or unwilling to sign the consent.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Patients with DILD	Blood sample collection	Patients will be recruited at the consultations of the Rennes Rare Lung Disease Competence Centre. These will be patients in stable condition or in acute exacerbation of IPF.

Primary Outcome Measures

Name	Time	Method
Determination of circulating CD163 serum concentration	Through study completion, an average of 4 years	Serum CD163 levels in patients with possible or certain DILD will be performed by ELISA technique (R\&D Systems kit, Minneapolis, MN).

Trial Locations

Locations (1)

Rennes University Hospital - Service de Pneumologie; 🇫🇷 Rennes, France